Tags

Type your tag names separated by a space and hit enter

COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
Histopathology. 2005 May; 46(5):561-8.H

Abstract

AIMS

There is considerable evidence that links COX-2 to the development of cancer. The aim of our study was to assess, by immunohistochemistry, COX-2 expression in ductal carcinoma in situ (DCIS) and its possible correlation with HER-2/neu, vascular endothelial growth factor (VEGF) expression and other common immunohistochemical parameters (p53, ER, PGR, Ki67).

METHODS AND RESULTS

Tissue samples of 49 archival cases of DCIS without any invasive component were analysed for COX-2, HER-2/neu, VEGF, oestrogen and progesterone receptors, Ki67 and p53 by immunohistochemistry using specific antibodies. COX-2 expression was detected in 43 (87.8%) tissue samples, of which 12 (24.5%) were graded as weak, 22 (44.9%) as moderate and nine (8.4%) as high expression. Only six (12.2%) lesions were negative for COX-2 expression. VEGF expression was detected in 93.8% of samples; 66.7% of lesions were found to be positive for HER-2/neu expression. Furthermore, COX-2 expression was significantly correlated with VEGF expression (P = 0.003). A significant positive correlation was also observed between COX-2 and HER-2/neu expression (P < 0.0001).

CONCLUSIONS

Our results suggest that COX-2 is highly expressed in DCIS and takes part in the molecular pathway implicated in progression of breast cancer and may provide a rationale for targeting COX-2 in preinvasive breast cancer therapy.

Authors+Show Affiliations

Surgical Pathology, Campus Bio-Medico University, Rome, Italy. g.perrone@unicampus.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

15842638

Citation

Perrone, G, et al. "COX-2 Expression in DCIS: Correlation With VEGF, HER-2/neu, Prognostic Molecular Markers and Clinicopathological Features." Histopathology, vol. 46, no. 5, 2005, pp. 561-8.
Perrone G, Santini D, Vincenzi B, et al. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features. Histopathology. 2005;46(5):561-8.
Perrone, G., Santini, D., Vincenzi, B., Zagami, M., La Cesa, A., Bianchi, A., Altomare, V., Primavera, A., Battista, C., Vetrani, A., Tonini, G., & Rabitti, C. (2005). COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features. Histopathology, 46(5), 561-8.
Perrone G, et al. COX-2 Expression in DCIS: Correlation With VEGF, HER-2/neu, Prognostic Molecular Markers and Clinicopathological Features. Histopathology. 2005;46(5):561-8. PubMed PMID: 15842638.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features. AU - Perrone,G, AU - Santini,D, AU - Vincenzi,B, AU - Zagami,M, AU - La Cesa,A, AU - Bianchi,A, AU - Altomare,V, AU - Primavera,A, AU - Battista,C, AU - Vetrani,A, AU - Tonini,G, AU - Rabitti,C, PY - 2005/4/22/pubmed PY - 2005/6/1/medline PY - 2005/4/22/entrez SP - 561 EP - 8 JF - Histopathology JO - Histopathology VL - 46 IS - 5 N2 - AIMS: There is considerable evidence that links COX-2 to the development of cancer. The aim of our study was to assess, by immunohistochemistry, COX-2 expression in ductal carcinoma in situ (DCIS) and its possible correlation with HER-2/neu, vascular endothelial growth factor (VEGF) expression and other common immunohistochemical parameters (p53, ER, PGR, Ki67). METHODS AND RESULTS: Tissue samples of 49 archival cases of DCIS without any invasive component were analysed for COX-2, HER-2/neu, VEGF, oestrogen and progesterone receptors, Ki67 and p53 by immunohistochemistry using specific antibodies. COX-2 expression was detected in 43 (87.8%) tissue samples, of which 12 (24.5%) were graded as weak, 22 (44.9%) as moderate and nine (8.4%) as high expression. Only six (12.2%) lesions were negative for COX-2 expression. VEGF expression was detected in 93.8% of samples; 66.7% of lesions were found to be positive for HER-2/neu expression. Furthermore, COX-2 expression was significantly correlated with VEGF expression (P = 0.003). A significant positive correlation was also observed between COX-2 and HER-2/neu expression (P < 0.0001). CONCLUSIONS: Our results suggest that COX-2 is highly expressed in DCIS and takes part in the molecular pathway implicated in progression of breast cancer and may provide a rationale for targeting COX-2 in preinvasive breast cancer therapy. SN - 0309-0167 UR - https://www.unboundmedicine.com/medline/citation/15842638/COX_2_expression_in_DCIS:_correlation_with_VEGF_HER_2/neu_prognostic_molecular_markers_and_clinicopathological_features_ L2 - https://doi.org/10.1111/j.1365-2559.2005.02132.x DB - PRIME DP - Unbound Medicine ER -